Skip to navigation Skip to content

Bone Marrow Stem Cell Transplant – HSCT

Share

In this article

About HSCT

The goal of hematopoietic stem cell transplant (HSCT) is to reset the immune system and stop inflammation that contributes to MS. A specific type of HSCT, “autologous,” or aHSCT, uses stem cells from your own body instead of using donor stem cells.

AHSCT is considered the safest form of HSCT in MS. There is growing evidence that aHSCT may be highly effective for people with relapsing MS who meet very specific characteristics. Learn more about the use of aHSCT in treating MS, including what’s involved in the procedure and cost.

Latest News and Updates on HSCT

Ongoing Research in HSCT

Worldwide, MS researchers are focusing on who may benefit from aHSCT and how to reduce its risks.
  • The Society is helping to facilitate the multicenter phase 3 clinical trial of HSCT (“BEAT-MS”). The trial began in 2020 and is now recruiting participants nationwide. Read more about this trial on the BEAT-MS website.
  • A clinical trial is getting underway at medical centers in Denmark, Netherlands, Norway and Sweden. The trial is testing treatment with aHSCT compared with alemtuzumab in people with active relapsing-remitting MS. Read more about this trial on clinicaltrials.gov.

More Information and Resources

Share


© 2021 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.